Not recruitingEUCTR 2018-004590-27
2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia
This historical record does not confirm current site availability.
Historical research recordMultiple countries
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
- Listed locations
- Sofia and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 300
- Sponsor
- Gedeon Richter Plc
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Bulgaria, Germany, Romania
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2018-004590-27
- Official title
Show the full official title
2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia
Recruitment & locations
Not recruitingSofia, Bulgaria · Targovishte, Bulgaria · Varna, Bulgaria
3 more locations
- Berlin, Germany
- Mannheim, Germany
- Timisoara, Romania
Registry details
Original registry record (opens in a new tab)A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Gedeon Richter Plc.
Who can participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as not recruiting.
Want to explore more studies?
Explore studiesRelated studies
A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mai...
A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia "ASPIRE OPEN-LABEL" (Aripiprazole...